Click here for Product Information


Leqvio® is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

  • in combination with a statin or statin with other lipid-lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin, or
  • alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.12



Learn more about the Leqvio® clinical trial data



Leqvio® is not reimbursed in Ireland at this time.


ASCVD,  atherosclerotic cardiovascular disease; CV, cardiovascular, CVD, cardiovascular disease; EAS, European Atherosclerosis Society; ESC, European Society of Cardiology; LDL-C, low-density lipoprotein cholesterol; LOS, length of stay


  1. Central Statistics Office. Vital Statistics Yearly Summary May 2021

  2. WHO. Cardiovascular diseases. Available at:

  3. EHN. European Heart Foundation European Cardiovascular Disease Statistics 2017.

  4. Activities in Acute Public Hospitals in Ireland 2019; HIPE_Report_2019.pdf (

  5. Visseren F, Mach F et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur J Prev Cardiol. 2022, 28 5115. doi:10.1093/eurjpc/zwab154

  6. First Report on the Healthy Ireland Outcomes Framework September, 2022

  7. Health in Ireland: Key Trends 2021.

  8. Manolis, AS et al. Trends in Cardiovascular Medicine. Vol 30, issue 8, Nov 2020 Pg 451-460.

  9. Mach F et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111–188.

  10. Ference BA. et al. Impact of Lipids on Cardiovascular Health: JACC Health Promotion SeriesJ Am Coll Cardiol. 2018 Sep 4;72(10):1141-1156

  11. Offiah, G., O’Connor, C., Kennedy, C. et al. The DA VINCI study: is Ireland achieving ESC/EAS guideline–directed LDL-C goals?. Ir J Med Sci (2022).

  12. Leqvio Summary of Product Characteristics. Accessed August 2022 at

Rate this content: 
No votes yet
March 2023 | IE189350

Ask Speakers


Medical Information Request

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions of the medicinal product is important to Novartis and the HPRA. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported via HPRA Pharmacovigilance, website: Adverse events could also be reported to Novartis preferably via or by email: [email protected] or by calling 01 2080 612.